e-Lung Computed Tomography Biomarker Stratifies Patients at Risk of Idiopathic Pulmonary Fibrosis Progression in a 52-Week Clinical Trial
Anand Devaraj, Finja Ottink, Christian Rennison-Jones, François-Xavier Blé, Olivier Joly, Adnan Azim, Stephen Gerry, George Harston, Kristoffer Ostridge, Peter M. George
Abstract
"e-Lung CT Biomarker Stratifies Patients at Risk of IPF Progression in a 52-Week Clinical Trial." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Topics & Concepts
MedicineBiomarkerClinical trialComputed tomographyInternal medicineImaging biomarkerLungRandomized controlled trialRadiologyMagnetic resonance imagingBiochemistryChemistryInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) ResearchInhalation and Respiratory Drug Delivery